



Last updated:

August 10<sup>th</sup>, 2019

**ITN Trial Status**

# Timeline Legend

**Yellow - Development:** Starts with protocol writing and other tasks including site selection, contracting and preparation and submission of an IND.

**Green - Enrollment:** Starts with the activation of the first site and continue until the last participant has first visit (LPFV).

**Blue - Follow up:** all trial activity starting with LPFV and concludes with last participant, last visit (LPLV).


**Red – Analysis:** Starts when all visits have been complete and includes data clean-up, database lock and reporting of clinical results.

# Allergy Trials - Development

## ITN076AD FEAST Pilot : Food Exposure Allergy Suppression. Phase II



## ITN084AD GRADUATE: Subcutaneous grass pollen allergen immunotherapy. Phase II



## ITN087AD EFFECT: EFFicacy of Etokimab in Peanut Allergy, a Randomized Controlled Trial. Phase II



# Allergy Trials – Enrollment / Analysis

## ENROLLMENT

ITN070AD LEAP Trio: LEAP Participants and their families. Observational [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02000000)




ITN079AD ACTIVATE: Exposure to Vaginal Microbiome in C-section Infants Phase II [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02000000)



## ANALYSIS

ITN050AD IMPACT: Peanut Oral Immunotherapy in Children Phase II [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02000000)




ITN57AD CATNIP: Anti-TSLP Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

Phase II [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02000000)




# Autoimmune Trials - Development

## ITN077AI BEAT-MS: BEst Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant for MS. Phase II



## ITN080AI REBOOT: Belimumab and Rituximab for Primary Membranous Nephropathy Phase II



## ITN086AI REVEAL: Evaluation of AMG 714 for Vitiligo. Phase II



# Autoimmune Trials – Enrollment / Analysis

## ENROLLMENT

ITN075AI BRAVOS: Brentuximab vedotin in diffuse cutaneous systemic sclerosis Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)




## ANALYSIS

ITN055AI CALIBRATE: Rituximab and Belimumab for Lupus Nephritis Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)




ITN059AI PAUSE: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)



# Transplant Trials – Enrollment

## ENROLLMENT

ITN062ST TEACH: Tolerance by engaging antigen during cellular homeostasis Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)



ITN063ST ALLTOL: ALLograft TOLerance Study

Observational [Clinicaltrials.gov](https://clinicaltrials.gov)



ITN073ST LITTMUS MGH : Liver Transplantation with Tregs at MGH Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)



# Transplant Trials– Follow Up

## FOLLOW UP

ITN056ST OPTIMAL: Senescence and Exhaustion Biomarkers of Operational Tolerance Following IS Withdrawal in Liver Transplant Phase II [Clinicaltrials.gov](https://clinicaltrials.gov)





# T1D Trials – Enrollment

## ENROLLMENT

ITN066AI T1DES: Long-Term Investigative Follow-up on Type 1 Diabetes    Observational    [Clinicaltrials.gov](https://clinicaltrials.gov)



# T1D Trials – Follow Up

## FOLLOW UP

ITN058AI EXTEND: Preserving Beta Cell Function with Tocilizumab in New Onset Type 1 Diabetes Phase II

[Clinicaltrials.gov](https://clinicaltrials.gov)



# ONGOING MECHANISTIC STUDY AND FOLLOW UP

ITN829AI INTREXON : ActoBio AG019 (L. lactis) and teplizumab

[Clinicaltrials.gov](https://clinicaltrials.gov)

ITN803ST deLTa: darTregs in Liver Transplantation

[Clinicaltrials.gov](https://clinicaltrials.gov)

ITN823ST IWITH Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

[Clinicaltrials.gov](https://clinicaltrials.gov)